- Home
- FRME vs SUPN Comparison
FRME vs SUPN Comparison
Compare FRME & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRME
- SUPN
- Stock Information
- Founded
- FRME 1893
- SUPN 2005
- Country
- FRME United States
- SUPN United States
- Employees
- FRME N/A
- SUPN N/A
- Industry
- FRME Major Banks
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- FRME Finance
- SUPN Health Care
- Exchange
- FRME Nasdaq
- SUPN Nasdaq
- Market Cap
- FRME 2.3B
- SUPN 2.6B
- IPO Year
- FRME N/A
- SUPN 2012
- Fundamental
- Price
- FRME $39.85
- SUPN $44.80
- Analyst Decision
- FRME Buy
- SUPN Buy
- Analyst Count
- FRME 3
- SUPN 2
- Target Price
- FRME $46.67
- SUPN $43.00
- AVG Volume (30 Days)
- FRME 192.4K
- SUPN 654.2K
- Earning Date
- FRME 10-23-2025
- SUPN 11-03-2025
- Dividend Yield
- FRME 3.60%
- SUPN N/A
- EPS Growth
- FRME 23.41
- SUPN 1411.53
- EPS
- FRME 3.85
- SUPN 1.14
- Revenue
- FRME $638,723,000.00
- SUPN $665,125,000.00
- Revenue This Year
- FRME $14.28
- SUPN $4.84
- Revenue Next Year
- FRME $4.02
- SUPN $17.69
- P/E Ratio
- FRME $10.38
- SUPN $38.93
- Revenue Growth
- FRME 6.22
- SUPN 5.55
- 52 Week Low
- FRME $33.13
- SUPN $29.16
- 52 Week High
- FRME $46.13
- SUPN $46.79
- Technical
- Relative Strength Index (RSI)
- FRME 47.05
- SUPN 58.16
- Support Level
- FRME $38.92
- SUPN $43.44
- Resistance Level
- FRME $40.48
- SUPN $46.72
- Average True Range (ATR)
- FRME 0.81
- SUPN 1.08
- MACD
- FRME -0.23
- SUPN -0.48
- Stochastic Oscillator
- FRME 29.43
- SUPN 40.60
About FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.